The Prior Restraint Era Begins: White House Moves Toward FDA-Style AI Model Approvals

Summary

The White House is implementing a 'prior restraint' approval system for frontier AI model releases, marking a dramatic shift toward government oversight of AI development. Officials have explicitly cited FDA drug approval processes as a regulatory template, and have already exercised veto power by blocking Mythos' access expansion—drawing concerns from industry observers that such timelines could chill innovation in the U.S. without parallel restrictions in China. Meanwhile, Anthropic continues accelerating its growth, announcing an expanded long-term compute deal with Google and leasing SpaceX's Colossus 1 supercomputer to expand capacity immediately. The company reported $44 billion in ARR and is pursuing a valuation exceeding $900 billion. Notably, Elon Musk has publicly praised Anthropic's safety-focused approach and motivations, contrasting sharply with ongoing litigation against OpenAI. The week also brought ongoing testimony in the Musk v. OpenAI trial and discussions between U.S. and Chinese officials on coordinated model access restrictions.

• U.S. and China discussing potential coordination on model access restrictions, suggesting diplomatic approach alongside domestic regulation

Editorial Opinion

The FDA-style prior restraint framework is a concerning regulatory direction that risks undermining U.S. competitiveness without ensuring parallel restrictions in China. Using pharmaceutical approval timelines for software models threatens to systematically slow innovation and advantage larger, better-resourced companies that can navigate prolonged regulatory cycles. Anthropic's ability to rapidly secure major compute partnerships shows companies adapting to the new landscape, but this framework could fundamentally alter the pace and nature of frontier AI development.